KI-Beratung Beta

Produktbild: Cancer II
Band 28

Cancer II

271,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

This book reviews recent breakthroughs in anti-cancer drug discovery.  Building on the previous volume in the series, it outlines some of the most significant developments that have occurred in the field in the subsequent period that have led to new drug approvals or promising clinical candidates.  The...

Beschreibung

This book reviews recent breakthroughs in anti-cancer drug discovery.  Building on the previous volume in the series, it outlines some of the most significant developments that have occurred in the field in the subsequent period that have led to new drug approvals or promising clinical candidates.  The volume is divided into chapters that each relate to a specific protein or protein class.  Each chapter provides an overview of the underlying biology and then emphasises the medicinal chemistry strategies and tactics that led to the most significant drugs and drug candidates.  A summary of clinical data and the future outlook for the field is also provided.  Each chapter is authored by experts in the topic and who have themselves made significant contributions to their respective fields.


Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

13.11.2018

Abbildungen

XIV, 475 p. 150 illus.

Herausgeber Michael J. Waring

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

13.11.2018

Abbildungen

XIV, 475 p. 150 illus.

Herausgeber Michael J. Waring
Verlag Springer
Seitenzahl

475

Maße (L/B/H)

24,1/16/3,2 cm

Gewicht

847 g

Auflage

1st ed. 2018

Sprache

Englisch

ISBN

978-3-319-75924-1

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: ProductSafety@springernature.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Cancer II

  • Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia.- Small Molecule Inhibitors of the Epidermal Growth Factor Receptor.- Small-Molecule Inhibitors of Bruton’s Tyrosine Kinase.- Inhibitors of Vascular Endothelial Growth Factor Receptor.- Inhibitors of the Fibroblast Growth Factor Receptor.- Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family.- Epigenetic Modulators.- Antibody–Drug Conjugates.- Isoform Selective PI3K Inhibitors for Treating Cancer.- Inhibitors of the Kynurenine Pathway.- Protein–Protein Interaction Inhibitors.- Small Molecule Inhibitors of ALK.